机构：[1]Department of Clinical Pharmacy, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu, China,临床药学部临床药学部四川省肿瘤医院[2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China,[3]Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China四川省人民医院
Cancer drug resistance has always been a major factor affecting the treatment of non-small cell lung cancer, which reduces the quality of life of patients. The clustered regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) technology, as an efficient and convenient new gene-editing technology, has provided a lot of help to the clinic and accelerated the research of cancer and drug resistance. In this review, we introduce the mechanisms of drug resistance in non-small cell lung cancer (NSCLC), discuss how the CRISPR/Cas9 system can reverse multidrug resistance in NSCLC, and focus on drug resistance gene mutations. To improve the prognosis of NSCLC patients and further improve patients' quality of life, it is necessary to utilize the CRISPR/Cas9 system in systematic research on cancer drug resistance.
基金：
This work was supported by Sichuan Cancer Hospital (Grant No.
YB2019001), Chengdu City Science and Technology Project
(Grant No.11PPYB010SF-289), and the Young Scholars
Foundation of Sichuan Provincial People’s Hospital (Grant
No. 30305030606 and 30305030859).
第一作者机构：[1]Department of Clinical Pharmacy, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu, China,[2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China,
共同第一作者：
通讯作者：
通讯机构：[1]Department of Clinical Pharmacy, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital and Institute, University of Electronic Science and Technology of China, Chengdu, China,[2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China,
推荐引用方式(GB/T 7714)：
Huang Lu,Liao Zhi,Liu Zhixi,et al.Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer[J].FRONTIERS IN PHARMACOLOGY.2022,13:doi:10.3389/fphar.2022.900825.
APA：
Huang, Lu,Liao, Zhi,Liu, Zhixi,Chen, Yan,Huang, Tingwenli&Xiao, Hongtao.(2022).Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer.FRONTIERS IN PHARMACOLOGY,13,
MLA：
Huang, Lu,et al."Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer".FRONTIERS IN PHARMACOLOGY 13.(2022)
医学